RxDoctor Payments Data

Craig Olin, MD

Internal Medicine · Old Greenwich, CTNPI 1588776173

Payments from drug & device makers

$302in general payments, 2019–2025

Across 7 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$156
  • Cleerly, Inc.$39
  • AbbVie$31
  • Novo Nordisk$24
  • ARS Pharmaceuticals Operations, Inc.$20
  • Lilly USA, LLC$20
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$302 in reported general payments places this provider in the 60th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$87,732
Medicare patients
205
Services billed
1,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$88,023
OzempicSemaglutide17$33,147
MyrbetriqMirabegron20$17,899
JardianceEmpagliflozin15$14,199
MounjaroTirzepatide11$14,092
XareltoRivaroxaban11$12,650
EntrestoSacubitril/Valsartan13$8,657
Testosterone14$5,019
SynthroidLevothyroxine Sodium40$4,291
Atorvastatin Calcium302$3,694
Tamsulosin Hcl65$2,092
Rosuvastatin Calcium88$2,000
Ezetimibe22$1,567
Metoprolol Succinate113$1,472
Nebivolol Hcl17$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$33,14717 claims
Lilly USA, LLCMounjaro$20$14,09211 claims
AbbVieSynthroid$31$4,29140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Old Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →